Close
ACHEMA MIDDLE EAST 2026

mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

The FDA has gone on to issue guidance on March 2, 2023 in order to give out recommendations to sponsors that will help in...

Pharma Responds To The Statutory Scheme Surge By The UK

The UK government has gone on to confirm its plans to move ahead with the proposed statutory scheme pharma rate surge. This means that...

A novel approach to attracting talent with a future-ready workplace

In the past employers have found recruiting top quality talent quite easy in Singapore, either from the  country’s highly educated local workforce, or from...

Clinical Trials Diversity – A Much To Be Explored Segment

Biopharma companies as well as policymakers know the significance of assessing medical and drug products across a broad range of racial and ethnic universes...

Terminal Sterilisation Process For Oligonucleotide Drugs

There is a new report which has gone on to review the processing of the present state of sterile oligonucleotide drug product. This includes...

New Initiatives To Boost Biomanufacturing In South Australia

Biomanufacturing industry is all set to get the much-needed push by the recent South Australian Government’s announcement when it comes to new initiatives as...

Research Says Fight Against Cancer Gets A Boost With STAT5

STAT5 has long been regarded as an interesting target versus cancer, but after several decades of research, it was relegated to the undruggable category....

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...